At ASCO, Pfizer Presents Data on New Mutation-Targeting NSCLC Drug

The investigational drug targets a mutation present in some NSCLC patients. It is unclear if Pfizer is planning to market the drug with a companion diagnostic that can gauge which lung cancer patients express the mutation.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.